Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 36, Issue 10, Pages 628-635Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tips.2015.07.002
Keywords
-
Categories
Funding
- Intramural NIH HHS [Z99 DA999999] Funding Source: Medline
Ask authors/readers for more resources
In contrast to traditional pharmacodynamic approaches to treat substance-use disorders (SUDs), the use of biologics (vaccines, monoclonal antibodies, and genetically modified enzymes) is based on a pharmacokinetic principle: reduce the amount of (and, ideally, eliminate) abused drug entering the central nervous system (CNS). Preclinical studies indicate that biologics are effective in both facilitating abstinence and preventing relapse to abused substances ranging from nicotine to heroin. While data are still emerging, the results from multiple clinical trials can best be described as mixed. Nonetheless, these clinical studies have already provided important insights using 'first-generation' tools that may inform the development of effective and commercially viable biologics to treat tobacco-, cocaine-, and methamphetamine-use disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available